Antibody persistence six years after two doses of combined hepatitis A and B vaccine

被引:15
作者
Burgess, Margaret A. [1 ]
McIntyre, Peter B. [1 ]
Hellard, Margaret [2 ]
Ruff, Tilman A. [3 ]
Lefevre, Inge [4 ]
Bock, Hans L. [4 ]
机构
[1] Childrens Hosp Westmead, Ctr Immunizat Res, Sydney, NSW 2145, Australia
[2] Burnet Inst, Ctr Populat Hlth, Melbourne, Vic 3004, Australia
[3] Univ Melbourne, Nossal Inst Global Hlth, Melbourne, Vic 3010, Australia
[4] GlaxoSmithKline Inc, Biol, Rixensart, Belgium
关键词
Antibody persistence; Long-term protection; Combined hepatitis A and hepatitis B vaccine; BOOSTER VACCINATION; FOLLOW-UP; CHILDREN; ADOLESCENTS; SCHEDULE; ADULTS; IMMUNOGENICITY; IMMUNIZATION; SAFETY; MEMORY;
D O I
10.1016/j.vaccine.2009.12.053
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Persistent immunity to hepatitis A and hepatitis B antibodies six years after vaccination of adolescents (aged 12-15 years) with a combined hepatitis A and B (HAB) vaccine following a 0,6 month or a 0,12 month schedule was assessed. Yearly (Year-2-6) serum samples were tested for anti-HAV and anti-HBs using EIA. Subjects with anti-HBs concentrations <10 mIU/mL (14/23) at Year-5 or Year-6, received an additional HBV vaccine dose similar to 12 months after Year-6. Blood samples were collected pre-booster and I month post-booster to assess booster response. 240 subjects were vaccinated in the study; at Year-6, data were available from 88 subjects. At that time 84.8% (39/46: 0,6 month) and 92.9% (39/42; 0,112 month) of subjects had anti-HBs concentrations >= 10 mIU/mL. All but one of the 14 boosted subjects responded to the additional HBV vaccine dose with anti-HBs concentrations >= 100 mIU/mL All seroconverted subjects who returned at Year-6 were seropositive for anti-HAV. Simplification, reduced number of doses and similar long-term persistence of immunity make the 0,6 month and 0,12 month schedule preferable for immunization against HAV/HBV in this population. (C) 2010 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2222 / 2226
页数:5
相关论文
共 22 条
[1]  
[Anonymous], 2000, Wkly Epidemiol Rec, V75, P38
[2]   Hepatitis B vaccine - do we need boosters? [J].
Banatvala, JE ;
Damme, P .
JOURNAL OF VIRAL HEPATITIS, 2003, 10 (01) :1-6
[3]   Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination [J].
Bauer, T ;
Jilg, W .
VACCINE, 2006, 24 (05) :572-577
[4]   Comparative immunogenicity and safety of two dosing schedules of a combined hepatitis A and B vaccine in healthy adolescent volunteers: an open, randomised study [J].
Burgess, MA ;
Rodger, AJ ;
Waite, SA ;
Collard, F .
VACCINE, 2001, 19 (32) :4835-4841
[5]   Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule [J].
Connor, Bradley A. ;
Blatter, Mark M. ;
Beran, Jiri ;
Zou, Bin ;
Trofa, Andrew F. .
JOURNAL OF TRAVEL MEDICINE, 2007, 14 (01) :9-15
[6]   Long-term antibody persistence induced by a combined hepatitis A and B vaccine in children and adolescents [J].
Diaz-Mitoma, Francisco ;
Law, Barbara ;
Subramanya, Archana ;
Hoet, Bernard .
VACCINE, 2008, 26 (14) :1759-1763
[7]   Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course? [J].
Kallinowski, B ;
Knöll, A ;
Lindner, E ;
Sänger, R ;
Stremmel, W ;
Vollmar, J ;
Zieger, B ;
Jilg, W .
VACCINE, 2000, 19 (01) :16-22
[8]   Immunogenicity of a combined hepatitis A and B vaccine in healthy young adults [J].
Knöll, A ;
Hottenträger, B ;
Kainz, J ;
Bretschneider, B ;
Jilg, W .
VACCINE, 2000, 18 (19) :2029-2032
[9]  
Lee SD, 1999, J MED VIROL, V59, P1, DOI 10.1002/(SICI)1096-9071(199909)59:1<1::AID-JMV1>3.0.CO
[10]  
2-F